Clinical trial · Interventional
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
NCT00467012CI-TRIAL-00006794completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Drug | Bevacizumab | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- step 1
- description
- 6 enrollment for 1 cycle(4 weeks)
- interventionNames
- Drug: bevacizumab
- Drug: Paclitaxel
- type
- EXPERIMENTAL
- label
- step 2
- description
- 114 enrollment through to meet the stopping criteria
- interventionNames
- Drug: bevacizumab
- Drug: Paclitaxel
Primary outcomes (2)
- measure
- Safety
- timeFrame
- throughout study
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
* At least 20 years old and obtained a written informed consent * Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer * HER2 negative * At least one measurable lesion based on RECIST criteria * No previous chemotherapy for metastatic breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.